Active, not recruitingPHASE1, PHASE2NCT06706388
Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation
Studying Dentatorubral pallidoluysian atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- n-Lorem Foundation
- Intervention
- nL-ATN1-002(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 17-17 years · MALE
- Timeline
- 2024 – 2026
Study locations (1)
- Columbia University, New York, New York, United States
Collaborators
Columbia University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06706388 on ClinicalTrials.govOther trials for Dentatorubral pallidoluysian atrophy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07221760Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutationn-Lorem Foundation
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07084311Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutationn-Lorem Foundation
- RECRUITINGNCT06273150Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers StudyUniversity College, London
- RECRUITINGNCT05489393CureDRPLA Global Patient RegistryCureDRPLA